Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.
2 reports, 2 independent
Updated Sep 13
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.The competition between the two companies is being tracked via analyst ratings from MarketBeat.1 source
Syndax and AbbVie are competing in the biopharma market.1 source
Keep exploring
The entities involved
-
Syndax Pharmaceuticals
business
Nothing else this week.
-
AbbVie
pharmaceutical company
Related events
- AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
- Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.
- AbbVie and Novo Nordisk are high-profile pharmaceutical stocks serving over 45 million people worldwide, with Cor acting as a significant distribution partner.
- AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.
- Pharmaceutical companies, including AbbVie and GSK, funded studies comparing drug spending, with Michael Johnson discussing Australia vs. New Zealand spending.